Gerresheimer (OTCMKTS:GRRMF – Get Free Report) is expected to announce its results before the market opens on Wednesday, November 4th. Analysts expect the company to post earnings of $0.3166 per share and revenue of $671.32 million for the quarter.
Gerresheimer Stock Performance
Shares of GRRMF stock opened at $37.47 on Tuesday. The stock’s 50-day moving average price is $31.88 and its 200 day moving average price is $29.61. Gerresheimer has a 52-week low of $19.16 and a 52-week high of $37.47.
Wall Street Analysts Forecast Growth
Several research analysts have weighed in on GRRMF shares. Deutsche Bank Aktiengesellschaft reiterated a “hold” rating on shares of Gerresheimer in a research note on Tuesday, August 4th. UBS Group upgraded Gerresheimer from a “sell” rating to a “neutral” rating in a research note on Tuesday, August 4th. Four analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Reduce”.
Get Our Latest Report on GRRMF
Gerresheimer Company Profile
Gerresheimer AG is a Germany-based manufacturer of pharmaceutical and healthcare packaging and drug-delivery systems. The company develops and produces primary packaging and components used to protect, store and administer medicines, serving pharmaceutical, biotechnology and healthcare customers worldwide.
Its product portfolio includes glass and plastic containers such as vials, ampoules, bottles, cartridges and syringes, as well as delivery systems including inhalers, injection pens, autoinjectors and other medical devices.
Read More
- Five stocks we like better than Gerresheimer
- AbbVie’s Humira Era Is Fading, But Its New Growth Engines Face Another Test
- GLP-1 Focus or Broader Peptide Exposure: Which ETF Has the Edge?
- Mortgage Rates Froze U.S. Housing, But These 3 Overseas Markets Still Pay Double Digits
- Big Tech Is Spending Billions on AIāThese 5 Stocks Are Getting Paid
Receive News & Ratings for Gerresheimer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gerresheimer and related companies with MarketBeat.com's FREE daily email newsletter.
